Projects

IrsiCaixa is involved in a hundred national and international research projects active each year, funded by both public and private entities.

Keywords

Research group

Researcher

From date

To date

GUMICHIP - Gut-Microbiota-on Chip for precision medicine

Project status

Ongoing

Start/End

2019

/

2021

External researchers

Rosa Villa (IMB-CNM-CSIC)

Strategic lines

Microbiome

Financing entity

MCIU/AEI/FEDER, UE

Project reference: RTI2018-096786-B-I00
Role of host immune factors as potential biomarkers for predicting response and resistance acquisition to palbociclib-based treatment in metastatic hormono sensitive breast cancer

Project status

Ongoing

Start/End

2021

/

2021

Principal investigator

Ester Ballana Guix

External researchers

Mireia Margelí

Participating entities

ICO, IGTP, B-ARGO

Strategic lines

Cancer

Emerging infectious diseases

Financing entity

Pfizer
SARS-CoV-2 vaccination in institutionalized elders: the challenge for a long-term immunity
Project status

Ongoing

Start/End

2020

/

2023

Principal investigator

Marta Massanella Luna

Participating entities

Direcció d’Atenció Primària – Metropolitana Nord (DAP-MN)
Fight AIDS and Infectious Diseases Foundation (FLS)
Germans Trias i Pujol Institute (IGTP)
Hospital Germans Trias i Pujol
- Funding entity:
Identifying ‘communicome’ profiles associated with HIV control

Project status

Ongoing

Start/End

2013

Principal investigator

Marta Ruiz Riol

Christian Brander

Strategic lines

Microbiome

Global infectious diseases

Financing entity

Spanish Ministry of Science and Innovation

This project investigates cytokine plasma level patterns and their association with relative HIV control and host innate and cellular immunity.
LKR155762 Combine use of vaccines an immune check blockers to boost CTL activity against the reservoir

Project status

Ongoing

Start/End

2017

/

2019

Principal investigator

Julia García Prado

Financing entity

MSD
Engineered enveloped VLPs with high-density antigen coating. A proof of concept for their application to animal health

Project status

Ongoing

Start/End

2018

/

2019

Principal investigator

Julià Blanco Arbués

Financing entity

Laboratorios Hipra, SA
RETIRE HIV, P01 Role of reservoir composition and T cell immunity in HIV rebound kinetics

Project status

Ongoing

Start/End

2017

/

2022

Principal investigator

Christian Brander

External researchers

Dennis Hartigan-O'Connor

Participating entities

University of California, Davis, Irsicaixa

Financing entity

NIH-NIAID
EnteroColonus-GAMES - Estudio prospectivo multicéntrico para explorar la relación entre las infecciones del torrente sanguíneo por Enterococcus faecalis y la neoplasia colorrectal
Project status

Ongoing

Start/End

2020

/

2022

External researchers

Juan Manuel Pericàs (IRB Lleida)

Strategic lines

Microbiome

Financing entity

Instituto de Salud Carlos III (ISCIII)
- Project reference: PI19/01898
Development of therapeutic antibodies against SARS-CoV-2
Project status

Ongoing

Start/End

2020

/

2022

Principal investigator

Julià Blanco Arbués

Participating entities

Germans Trias i Pujol Institute (IGTP)
Hospital Germans Trias i Pujol
Barcelona Supercomputing Center & ICREA
IRTA-CReSA
- Funding entity
CUTHIVAC HIV skin vaccine

Project status

Ongoing

Start/End

2010

Principal investigator

Christian Brander

Beatriz Mothe Pujadas

Participating entities

Université Pierre et Marie Curie, University of Regensburg, FIT Biotech Oy Ltd, Charité-Universitätsmedizin Berlin, St George’s University of London, MRC Medical Research Council, IMPACTA, Centre National de la Recherche Scientifique, INSERM, Instituto Nacional de Saúde, GENEART AG, NOVAMEN

Strategic lines

Microbiome

Global infectious diseases

Financing entity

European Commission

The CUTHIVAC project is an innovative needle-free skin vaccination strategy against HIV and other infectious diseases.